Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High – Time to Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $12.72 and last traded at $12.64, with a volume of 3058268 shares. The stock had previously closed at $12.33.

Analysts Set New Price Targets

A number of equities research analysts have commented on AMRX shares. JPMorgan Chase & Co. increased their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Barclays assumed coverage on Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Amneal Pharmaceuticals Stock Up 2.5%

The firm has a 50-day simple moving average of $11.34 and a 200 day simple moving average of $9.69. The company has a market cap of $3.97 billion, a price-to-earnings ratio of 632.32 and a beta of 1.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Activity

In other news, Director Ted C. Nark sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the transaction, the director owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the sale, the executive vice president directly owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 231,856 shares of company stock valued at $2,743,724 in the last quarter. Insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BlackBarn Capital Partners LP grew its holdings in shares of Amneal Pharmaceuticals by 19.6% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after acquiring an additional 564,916 shares during the period. JPMorgan Chase & Co. raised its holdings in Amneal Pharmaceuticals by 22.0% during the second quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock worth $10,779,000 after purchasing an additional 240,676 shares during the last quarter. Walleye Capital LLC boosted its position in Amneal Pharmaceuticals by 26.9% during the second quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock worth $5,735,000 after purchasing an additional 150,104 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Amneal Pharmaceuticals by 51.3% in the first quarter. Acadian Asset Management LLC now owns 2,598,294 shares of the company’s stock valued at $21,759,000 after purchasing an additional 880,471 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Amneal Pharmaceuticals by 21.8% in the second quarter. Allspring Global Investments Holdings LLC now owns 73,754 shares of the company’s stock valued at $606,000 after purchasing an additional 13,187 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.